The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: Nuuvera

21 Mar 2018 13:28

RNS Number : 4747I
FastForward Innovations Limited
21 March 2018
 

 

21 March 2018

 

FastForward Innovations Limited

("FastForward"")

Investee Company Update:

UPDATE ON PLAN OF ARRANGEMENT WITH APHIRA INC.

FastForward notes the announcement today by investee company Nuuvera Inc. ("Nuuvera" (TSXV: NUU)), a public company formed to capitalize on the global trend towards the legalisation of medical cannabis, in which FastForward currently has a holding of 3.4%. The announcement is set out below without material changes or adjustments:

LEAMINGTON, ON and TORONTOMarch 20, 2018 /CNW/ - Nuuvera Inc. (the "Company" or "Nuuvera") (TSXV:NUU) and Aphria Inc. ("Aphria") (TSX: APH and US OTC: APHQF) are pleased to announce that, at the special meeting of shareholders of Nuuvera held today (the "Meeting"), the shareholders of Nuuvera overwhelmingly voted in favour of a special resolution to approve the proposed plan of arrangement with Aphria previously announced on January 29, 2018(the "Arrangement") pursuant to which, among other things, Aphria will acquire all of the issued and outstanding shares of Nuuvera not already owned by it.

 

The Arrangement required approval by: (i) 66⅔% of the votes cast by shareholders present in person or represented by proxy at the Meeting; and (ii) a simple majority of the votes cast by shareholders present in person or represented by proxy at the Meeting, excluding the votes cast by such shareholders as are required to be excluded pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101").

 

A total of 60,129,430 Nuuvera shares, representing approximately 67.15% of the outstanding Nuuvera shares, were represented in person or by proxy at the Meeting. Of the votes cast with respect to the Arrangement, an aggregate of 60,073,288 Nuuvera shares were voted in favour of the Arrangement, representing approximately 99.90% of the votes cast on the resolution. In addition, an aggregate of 47,193,288 Nuuvera shares, representing approximately 99.88% of the votes cast on the resolution excluding such shareholders as are required to be excluded pursuant to MI 61-101, were voted in favour of the Arrangement.

 

It is expected that Nuuvera will apply for a final order of the Ontario Superior Court of Justice (Commercial List) on March 22, 2018. Completion of the Arrangement remains subject to other customary closing conditions, including the aforementioned court order. Assuming that the conditions to closing are satisfied or waived, it is expected that the Arrangement will be completed on or around March 23, 2018. Following completion of the Arrangement, Nuuvera will be de-listed from the TSX Venture Exchange and applications will be made for Nuuvera to cease to be a reporting issuer.

 

Further information about the Arrangement is set forth in the materials prepared by the Company in respect of the Meeting which were mailed to Nuuvera shareholders and filed under Nuuvera's profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

 

About Nuuvera

 

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in GermanyIsrael and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA - Avanti and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

 

For more information about Nuuvera, please visit: www.nuuvera.com

 

CONTACTS:

 

FastForward Innovations Limited info@fstfwd.co

Sue Saunders/ Ian Burns

Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396

James Biddle / Roland Cornish

Optiva Securities Limited (Broker) Tel: +44 (0) 203 411 1881

Ed McDermott

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUAUORWBAOUAR
Date   Source Headline
6th Apr 20167:00 amRNSInvestee Company Update
5th Apr 20162:50 pmRNSInvestee Company Update
4th Apr 20167:00 amRNSInvestee Company Update: Schoold
31st Mar 20161:18 pmRNSInvestee Company Update
9th Mar 201610:00 amRNSExpected announcement date of 2016 Final Results
4th Mar 201610:01 amRNSInvestee Company Update
3rd Mar 20165:15 pmRNSInvestee Company Update: Vemo
19th Feb 20167:00 amRNSGrant of Options
18th Feb 20168:21 amRNSHolding(s) in Company
15th Feb 20165:23 pmRNSTransaction in Own Shares
15th Feb 20161:26 pmRNSFurther Investment in Yooya
12th Feb 20165:19 pmRNSCompletion Placing
8th Feb 20166:20 pmRNSPlacing Update
2nd Feb 20167:00 amRNSInvestee Company Update
28th Jan 20167:00 amRNSPlacing
27th Jan 20164:47 pmRNSLorne Abony Appointed as Chief Executive Officer
26th Jan 20167:00 amRNSInvestment
11th Jan 20164:27 pmRNSHolding(s) in Company
11th Jan 201612:33 pmRNSInvestment in Yooya Media
6th Jan 20161:47 pmRNSDirectorate Change
5th Jan 20165:19 pmRNSCompletion of investment in VEMO and Placing
29th Dec 20157:00 amRNSNew Website
22nd Dec 20153:08 pmRNSPlacing and Director Dealing
21st Dec 20155:56 pmRNSAcquisition of shares in Vemo Education, Inc
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
17th Dec 20157:00 amRNSInvestee Company Update - Vemo Education Inc
2nd Dec 20154:26 pmRNSHolding(s) in Company
26th Nov 201511:02 amRNSPlacing
25th Nov 20157:00 amRNSInvestee Company Update - Vemo Education Inc
23rd Nov 20156:05 pmRNSHolding(s) in Company
23rd Nov 201511:36 amRNSResult of General Meeting
23rd Nov 20157:00 amRNSAcquisition
13th Nov 20157:00 amRNSHalf Yearly Report
10th Nov 20151:32 pmRNSPlacing
3rd Nov 20157:00 amRNSProposed Name Change
29th Oct 20157:00 amRNSCorporate Update
22nd Oct 20153:35 pmRNSInvestee company Intensity Therapeutics update
14th Oct 20157:53 amRNSInvestment in Factom
6th Oct 20158:03 amRNSInvestment in Intensity Therapeutics Inc
21st Sep 20157:00 amRNS10% Acquired of nanopayment developer SatoshiPay
18th Sep 201510:32 amRNSResult of AGM
8th Sep 20157:00 amRNSIssue of Equity
7th Sep 20157:00 amRNSAcquisition
1st Sep 20157:03 amRNSIssue of Equity
31st Jul 20158:24 amRNSUpdate on Investment review
28th Jul 201511:36 amRNSResult of EGM
13th Jul 20158:00 amRNSChange of Investing Policy and Name
13th Jul 20157:00 amRNSDirectorate Change
23rd Jun 20152:36 pmRNSNotice of AGM
17th Jun 20159:34 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.